310210.KQ Voronoi, Inc. Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
11:00
Aug 04
Biotech, robotics policy catch-up rally.
Korean biotech and robotics stocks are catching up to US biotech strength, supported by a 1 trillion won government policy fund for Phase 3 clinical trials, KOSDAQ tier system expectations, and specific names like Voronoi (lung cancer drug) directly benefiting. Robotics names like Robotis and SPG are also strongly rebounding.
310210.KQ
HIGH
08:36
Aug 04
Phase 3 support fund drives biotech.
The government is launching a 1 trillion won fund specifically for Phase 3 clinical trials, a massive increase from the previous ~300bn won level, easing funding barriers for small biotech firms. This, combined with US biotech indices rallying since June while Korean biotech stocks kept falling, creates a catch-up opportunity. Companies like Voronoi (lung cancer Phase 3) and DND Pharmatech are prime beneficiaries, with Voronoi surging 19% on the news.
MED

About 310210.KQ Analyst Coverage

Buzzberg tracks 310210.KQ (Voronoi, Inc.) across 1 sources. 2 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 2 total trade ideas tracked. Past 7 days: 2 bullish. Latest voices: Lee Kwon-hee.